The affordable insulin crisis is a pricing and distribution problem, not a scientific one. With manufacturing costs as low as $2-$10 per vial and sale prices up to $300, a non-profit can create a sustainable model by operating within this massive margin, aiming for a consumer price of around $30.
Operating as a non-profit removes the fiduciary duty to investors, granting freedom to prioritize the mission over profits. However, this lack of a potential return on investment (ROI) is a major hurdle, often causing potential donors to reject the pitch, even if they claim they would have invested in a for-profit version.
The high cost of insulin isn't from manufacturing but from the complex distribution chain of wholesalers, pharmacies, and insurers. Project Insulin's core strategy is to bypass this system entirely with a direct-to-patient mail-order pharmacy model, effectively eliminating the middlemen who inflate the final price.
A founder initially resented his early board for constantly challenging his ideas. He later realized that this rigorous pushback during the low-stakes initial years was invaluable training. It forced him to refine his pitches and requests, preparing him for high-stakes meetings where clarity and justification were critical.
The founder of Project Insulin reveals it took five and a half years of work—primarily fundraising and planning—just to sign the contract with a CDMO to begin drug development. This highlights the immense, often invisible, runway required before the 'real' scientific work starts, demanding extreme patience and long-term commitment.
Unlike for-profit ventures driven by rapid ROI, a non-profit biotech's timeline is dictated by maximizing the chances of success. The founder is comfortable if it takes five years just to complete pre-IND submissions, as the primary goal is ensuring the drug gets approved by the FDA, not rushing to market for investors.